Topics

BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

15:20 EDT 13 Sep 2019 | SCRIP

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio...

      

Related Stories

 

Original Article: BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

NEXT ARTICLE

More From BioPortfolio on "BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...